HEALTHCARE PROFESSIONALS

Clinical Data

Vencarm® XL meets all the relevant regulatory requirements of a bioequivalent medicine (Reference product (TREVILOR® retard (venlafaxine) 150mg [Pfizer Pharma GmbH, Germany]/ EFEXOR XL® (venlafaxine prolonged-release capsules) (Pfizer Limited, UK)).1 Bioequivalence studies of the 150 mg strengths (Fasting, Fed & Steady state [under fed conditions]) of the Test (venlafaxine XL) and Reference product (TREVILOR® retard 150 mg [Pfizer Pharma GmbH, Germany]/ EFEXOR XL® (Pfizer Limited, UK)), were carried out comparing the mean plasma concentrations, for both Venlafaxine and the major metabolite, O-Desmethylvenlafaxine. The graphs for Venlafaxine are provided.

Single dose study comparing Vencarm XL 150mg and Trevilor retard/ Efexor XL 150mg under fasted conditions

Single dose study comparing Vencarm XL 150mg and Trevilor retard/ Efexor XL 150mg under fed conditions

Steady State study comparing Vencarm XL 150mg and Trevilor retard/ Efexor XL 150mg under fed conditions

References: 1) Data on file. 1010344221 v 2.0 September 2019.

TRUSTED BRANDS.
DEPENDABLE SUPPLY CHAIN.

For further information please call: 01730 231148,
email: info@aspirepharma.co.uk or visit www.aspirepharma.co.uk
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Vencarm XL (venlafaxine), please see the abbreviated prescribing information.

Revision reference – Vencarm XL_6_25.08.2020

More products available
in this range:
Click to view their
individual websites